AVLN.US Avalyn Pharma Inc. Common Stock

Healthcare Biotechnology USA Stocks
30.28 USD
Close of Nov 14, 2026
22.24 40.17
Market cap
USD 1.34B
P/E
-
P/B
3.40x
ROE
-30.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is AVLN.US undervalued?

Graham number

The Graham number of Avalyn Pharma Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Avalyn Pharma Inc. Common Stock fundamental analysis

No fundamental analysis for Avalyn Pharma Inc. Common Stock yet.

Avalyn Pharma Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmon…

Full company profile